<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200610047724N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-08-11</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>Evaluation of watchful waiting strategy in children with acute otittis media</public_title>
      <acronym>child otitis media study(COMS)</acronym>
      <scientific_title>Evaluation of watchful waiting  strategy in the treatment of acute otitis media in children 6 month to 18 years of age</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48885</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Other design features: The watchful waiting intervention in our study is non-pharmacological. Patients do not have a control group. All patients put on watchful waiting strategy at first except in critical cases. Within 72 hours, those patients who do not respond properly will receive antibiotics.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Acute otitis media.</hc_freetext>
      <i_freetext>All patients enrolled to the study with a diagnosis of middle ear infection, if they do not meet the conditions for immediate and emergency antibiotic administration, the treatment decision will be based on watchful waiting ,that means the child will be monitored up to 72 hours without antibiotics prescription (only simple analgesics such as acetaminophen if necessary).  Antibiotics are prescribed if warning signs such as worsening of the patient's general symptoms, uncontrollable fever, vomiting, lethargy and intolerance to food are detected within 72 hours.  During this period, we monitor the child's symptoms through face-to-face or telephone examination and observation of symptoms and signs .The group has been treated without treatment only under supervision will be the watchful waiting group and those who have not responded in this way and we have to prescribe antibiotics will be in the antibiotic group.Then both groups will be compare in terms of different variables such as sex ,age, post nasal discharge ,adenoid hypertrophy unilateral or bilateral ears involvement and history of atopic conditions..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Demographic Information  of Patients, Clinical Symptoms and signs,  therapeutic approach including Watchful and waiting versus antibiotic therapy  will be available

When:
Start the access period 3 months after printing the results

To whom:
All academic and non-academic researchers

Conditions:
In order to design and perform similar interventions at a larger size, access to data and applied analysis is possible.

Where to obtain:
Personal email, mobile number and work phone number of researcher.

How to obtain:
Documents will be sent within 4 to 8 weeks after the application

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahnaz Haghighi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.4 , Mollasadra street  , Mollasadra medical center , 3Floor</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>کدپستی۱۵۴۱۱-۷۱۹۳۶</zip>
        <telephone>+98 71 3647 2787</telephone>
        <email>haghighi0005@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahnaz Haghighi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.4 , Mollasadra street  , Mollasadra medical center , 3Floor</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>کدپستی۱۵۴۱۱-۷۱۹۳۶</zip>
        <telephone>+98 71 3647 2787</telephone>
        <email>haghighi0005@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>children aged between 6 months and 18 years,
the presence of mild to moderate AOM, fever less than 39 ° C,no toxicity or pussy discharge from the ears
physical exam suggestive for AOM ( acute otitis media)</inclusion_criteria>
      <agemin>6 months</agemin>
      <agemax>15 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>recent antibiotic use
facial or cranial deformities
immunodeficiency, malnutrition,HIV
history of  hearing problems, tympanic membrane perforation
frequent history of AOM
Down syndrome
poor compliance</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>All patients enrolled to the study with a diagnosis of middle ear infection, if they do not meet the conditions for immediate and emergency antibiotic administration, the treatment decision will be based on watchful waiting ,that means the child will be monitored up to 72 hours without antibiotics prescription (only simple analgesics such as acetaminophen if necessary).  Antibiotics are prescribed if warning signs such as worsening of the patient's general symptoms, uncontrollable fever, vomiting, lethargy and intolerance to food are detected within 72 hours.  During this period, we monitor the child's symptoms through face-to-face or telephone examination and observation of symptoms and signs .The group has been treated without treatment only under supervision will be the watchful waiting group and those who have not responded in this way and we have to prescribe antibiotics will be in the antibiotic group.Then both groups will be compare in terms of different variables such as sex ,age, post nasal discharge ,adenoid hypertrophy unilateral or bilateral ears involvement and history of atopic conditions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Percentage of children recovering without antibiotics. Timepoint: 72 hours , a week and two weeks after treatment. Method of measurement: Improving the patient's symptoms, including fever and autoscopic ear examinations.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Clinical improvement, elimination of ear pain, restlessness, anorexia, general well-being and elimination of inflammation of the eardrum in the examination. Timepoint: First visit ,48 to 72 hours later, One to two weeks after the first visit. Method of measurement: Ear examination and current present illness.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-06-11</approval_date>
        <contact_name>Ethic commitee of Islamic Azad University Kazeroon Branch</contact_name>
        <contact_address>Shiraz,No.4,Mollasadra Street,Mollasadra medical center,3Floor Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
